25713888
BACKGROUND	Midodrine is an - agonist prodrug of desglymidodrine used for the management of hypotension .
BACKGROUND	Midodrine has demonstrated usefulness in hepatorenal syndrome .
OBJECTIVE	The objective of the present work was to study the role of midodrine in patients with non-azotemic cirrhosis with tense ascites .
METHODS	This prospective randomized double blind placebo-controlled study was conducted on 67 non azotemic inpatients with liver cirrhosis and tense ascites ( 52 men and 15 women ; age range , 45-72 ) .
METHODS	One patient declined to participate in the study , 33 patients were randomly assigned to take midodrine hydrochloride , and 33 patients were randomly assigned to take placebo .
METHODS	Out of 67 enrolled patients , 60 patients ( 30 : in midodrine group ; 30 : in placebo group ) completed the study and 6 patients lost to follow up .
METHODS	Patients were assessed for patients characteristics , history of tapping their ascetic fluid , laboratory values , and Doppler parameters before and after the study .
METHODS	Average 24-h urine volume was assessed before and after the start of the study .
RESULTS	significant reduction in body weight and abdominal girth was observed after 2 weeks of midodrine therapy .
CONCLUSIONS	Midodrine appeared to be effective in lowering body weights and abdominal girths of non azotemic cirrhotic patients with tense ascites .

